Switching From an Originator to a Biosimilar Mid-Treatment
Changing from a reference biologic to an approved biosimilar part-way through a course is a recognised prescriber decision, not a downgrade and not a pharmacy substitution. It arrives at a specific moment: the cost of finishing treatment suddenly becomes manageable, and a family has days to decide.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
Is It Safe to Switch to a Biosimilar Mid-Treatment?
In regulatory terms, yes. An approved biosimilar has already had to show no clinically meaningful difference from its reference product before it could be sold. A supervised mid-course change is therefore not expected to alter safety or effect. It is a decision your oncologist makes and records — not one a counter makes for you.
The question almost never arrives in the abstract. Treatment starts on the originator because that is what exists. Then a cheaper approved version reaches the market, or a scheme adds it, and the arithmetic for the remaining cycles changes overnight. That is what happened with nivolumab in India: a domestically manufactured biosimilar launched in January 2026, ahead of the originator's Indian patent lapsing in May 2026. Families already several cycles in were the first to ask this question.
India's framework matters here, and it is often misdescribed. These products are regulated as similar biologics under the CDSCO and Department of Biotechnology Guidelines on Similar Biologics. India does not operate a separate interchangeability designation of the kind the US FDA grants. The practical consequence works in the patient's favour: a biologic is not swapped automatically at dispensing. The prescription names the product, so a change has to be written by the prescriber.
What the accumulated evidence says. Across biologics generally, switching between a reference product and its approved biosimilar under prescriber supervision has not produced a loss of clinical effect or a new safety signal, and in 2022 the European Medicines Agency and the Heads of Medicines Agencies issued a joint statement to that effect for EU-approved biosimilars. That is European regulatory practice, not Indian law, and it is worth stating the limit honestly: dedicated switching studies specifically in checkpoint inhibitors are still few, because these biosimilars are recent. The reassurance rests on the approval standard and on class-wide switching experience, not on a large trial in this exact setting.
Did you know?
India has no interchangeability designation of the kind the US FDA grants. No pharmacy can quietly swap your biologic brand on its own — a mid-course change has to be written by the prescriber and entered in your file. If the brand on the vial differs from the brand on your prescription, you are entitled to ask why.
Does Your Response Change If You Switch Brands?
Not by design. Both products act on the same target, at the same dose and on the same schedule. Equivalence of clinical effect is the condition on which the biosimilar was approved. Your own response is driven by cancer type, stage, prior treatment and biomarker status — none of which change when the label does.
That is the answer to the fear. The more useful question is what genuinely does move when the brand moves, because several things do — and almost all of them are administrative rather than clinical.
| What is being asked about | Does it change with the switch? | Why |
|---|---|---|
| Active molecule and its target | No | The biosimilar is the same molecule, approved against a named reference product |
| Dose and infusion schedule | No | Set by the approved indication and the labelled dosing, not by the manufacturer |
| The regulatory standard applied | No | Both hold marketing approval; the biosimilar had to prove comparability to get it |
| Expected response in your indication | No, not by design | Equivalent clinical effect is the basis of approval; individual outcome still varies |
| Excipients, vial size, presentation | Possibly | Formulation details may differ; relevant mainly to rare reactions and to pharmacy handling |
| Immunogenicity monitoring practice | Possibly | Comparative immunogenicity is assessed at approval; some teams watch the first switched cycles more closely |
| Brand and batch recorded each cycle | Yes — and it must be | Required to attribute any later adverse event to the right product |
| Insurance or scheme pre-authorisation | Often, yes | Approvals are increasingly issued at brand level and may need reissuing |
| Cost of the cycles still to come | Yes | That is the reason the switch is being considered at all |
Summarised from the CDSCO and Department of Biotechnology Guidelines on Similar Biologics and from standard pharmacovigilance practice. Applied case by case by the treating team.
Who Decides Whether You Switch?
Your treating oncologist. The change has to be prescribed, because a biologic is not substituted at the counter in India. Three other parties shape the decision without making it: the hospital pharmacy through what it can supply, your insurer or scheme through the brands it reimburses, and you — because the reason is usually cost.
Being clear about who holds which decision is what stops this becoming a negotiation nobody is in charge of. It also tells a family exactly whose answer they are waiting on.
| Who | What they decide | What is not theirs to decide |
|---|---|---|
| Treating oncologist | Whether a switch is clinically appropriate, at which cycle, and what monitoring follows | They cannot make the change without writing and recording it |
| Hospital pharmacy | Which approved brands are stocked, sourced and supplied, and how cold chain is held | Substituting one biologic brand for another on its own initiative |
| Insurer or state scheme | Which product it reimburses, at what rate, and whether pre-authorisation is reissued | Directing your clinical care or the timing of a cycle |
| You and your family | Whether to accept the switch, and to disclose the cost pressure driving it | Sourcing the vial yourselves; a biologic must come through the treating hospital |
One practical point that families consistently underuse: an oncologist cannot weigh a cost you have not told them about. If the household is deciding between finishing the course and stopping early, say so. That is clinical information, not a private matter.
Who this page is not for
This page is not for you if a checkpoint inhibitor or another cancer biologic has not been raised as an option for your specific cancer, stage and biomarker profile. Most patients in India are not candidates for immunotherapy at all, and a cheaper version of a medicine that is not indicated for you is still not indicated for you.
It also does not apply to ordinary chemotherapy tablets and injections. Those are small molecules with generic equivalents and a different substitution framework entirely. Nothing here transfers to them.
The medicines discussed need specialist caution, or are unsuitable, where a patient has active autoimmune disease, is on high-dose immunosuppression, has had an organ or stem-cell transplant, is pregnant or breastfeeding, or is too frail to tolerate an immune-related adverse event. Those limits are unchanged by which brand is used, and a switch never widens them.
And this page is not a price quote, not a recommendation of any named brand or manufacturer over another, and not a route to obtain the medicine. There is no legitimate way to buy these products outside a prescription-only, hospital-administered setting.
How Much Does Switching Mid-Course Actually Save?
It depends on how many cycles remain, not on the price of one vial. Multiply the per-cycle difference by the cycles still planned, then subtract nothing else — day-care charges, monitoring bloods and response scans do not change with the brand. The saving sits on the drug line alone.
The published Indian figures are worth stating precisely, and dating. Reporting around the first domestically manufactured nivolumab biosimilar, launched in January 2026, placed it at roughly a quarter of the reference price — months before the originator's Indian patent lapsed in May 2026. Pembrolizumab's protection is expected to begin lapsing around 2028-29, which is why families on that molecule are being told to expect a similar conversation later rather than now. All of these figures are indicative only, as of August 2026, and are drawn from manufacturer announcements and published news reporting. None of them is a hospital rate card.
Two things regularly surprise families at this point. First, if an insurer pays a fixed sum per cycle, a cheaper brand can reduce the insurer's outlay rather than the household's — worth confirming before the switched cycle, not after. Second, a switch decided late in a course saves less than it appears to, simply because fewer cycles remain to save on. Our companion page on insurance and biosimilars sets out how claims and pre-authorisations behave when the brand changes.
India's experience of this is older than immunotherapy. Biosimilar rituximab and trastuzumab reshaped the cost of lymphoma and HER2-positive breast cancer treatment here years before checkpoint inhibitors reached the same point, and mid-course switching was routine in both. The pattern that follows a patent expiry is well established; only the molecule is new.
What Should You Check Before and After a Mid-Course Switch?
Seven checks cover it: approval status, your own indication, the whole-course cost, insurance, sourcing, documentation, and the scan schedule. A treating team will work through all seven without hesitation, and none of these questions is a challenge to them.
- Is the new product CDSCO-approved as a similar biologic to the same reference molecule? Ask for the brand name written on the prescription, not just the molecule.
- Is your indication approved directly, or by extrapolation? Either answer can be reasonable. You are entitled to know which one applies to you.
- How many cycles remain, and what is the difference across all of them? One vial is the wrong unit for this decision.
- Will your insurer or scheme reimburse the new brand, and must pre-authorisation be reissued? Settle this before the switched cycle, in writing.
- Where is the vial sourced, and may you see the batch number and invoice? Cold chain and provenance are fair questions on any biologic.
- Are the brand and batch entered in the file every cycle from now on? This is what allows a later side effect to be attributed correctly.
- Is the response-assessment schedule unchanged? A brand change is not a reason to bring a scan forward, delay one, or reinterpret one.
The authenticity risk lives inside the price gap, and it should not be softened. Counterfeit checkpoint inhibitors have been reported entering the Indian market around patent and exclusivity changes, and a large, sudden price difference is exactly the environment in which a fake vial finds a buyer. A mid-course switch is a moment of maximum exposure, because the family is already expecting the price to fall. Two rules follow. These products should be dispensed and administered through the treating hospital's own pharmacy — never sourced privately, through an intermediary, or online, however credible the offer looks. And ask to see the vial, the batch number, the invoice and how cold chain was maintained. Our pages on counterfeit immunotherapy drugs in India and verifying that a vial is genuine set out the checks in detail.
Related reading
- Rituximab Biosimilars in India: The Original Cost Story — where India's biosimilar switching experience began.
- Trastuzumab Biosimilars in India — the same pattern in HER2-positive breast cancer.
- Insurance and Biosimilars: Will Your Claim Be Affected? — pre-authorisation and reimbursement when the brand changes.
- Immunotherapy Medicines Explained — the reference section this page belongs to.
- Immunotherapy at CION Cancer Clinics — how immunotherapy is assessed, administered as day care, and monitored.
Editorial information about a class of medicines and a treatment decision — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. Pricing and regulatory statements are indicative only, dated to August 2026, and drawn from published manufacturer announcements, regulatory guidance and news reporting. Whether a switch applies to your treatment is a decision for your treating oncologist.